Other

DC on fast track to decriminalizing pot possession

It took nearly 15 years after voters approved medical marijuana for it to become available in Washington, D.C., but the next major change to pot laws in the U.S. capital is on the fast track.

Nov 02, 2013
popularity not rated yet | comments 0

AstraZeneca profits and revenues fall

British drugmaker AstraZeneca reported Thursday that third-quarter net profit fell 17.5 percent to 1.25 billion pounds ($200 billion) as the patents on older drugs expired.

Oct 31, 2013
popularity not rated yet | comments 0

Indian drug giant Dr Reddy's Q2 profit up 69%

India's second-largest drugmaker Dr Reddy's Laboratories on Tuesday reported a 69.4 percent jump in quarterly net profit, as profit margins rose helped by improved sales.

Oct 31, 2013
popularity not rated yet | comments 0

Bayer says new products push profits higher in Q3

German chemicals and pharmaceuticals group Bayer, maker of Aspirin, said on Thursday that new pharmaceutical products and favourable agrochemical prices gave profits a fillip in the third quarter.

Oct 31, 2013
popularity not rated yet | comments 0

CEO of drug maker Teva out ahead job cuts (Update)

Israeli drug manufacturer Teva Pharmaceuticals Ltd. announced Wednesday its CEO had resigned, following a public uproar over a contentious restructuring plan set to cut thousands of jobs worldwide.

Oct 30, 2013
popularity not rated yet | comments 0

Results from many large clinical trials are never published

A new analysis of 585 large, randomized clinical trials registered with ClinicalTrials.gov finds that 29 percent have not been published in scientific journals. In addition, nearly 78 percent of the unpublished trials had ...

Oct 29, 2013
popularity 4 / 5 (4) | comments 2

Pfizer 3Q net falls due to generics, higher costs

Pfizer Inc.'s third-quarter profit dropped 19 percent as competition from generic drugs continued to cut sales, while lower operating expenses failed to offset higher taxes and charges.

Oct 29, 2013
popularity not rated yet | comments 0